Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men

Rishi Sharma, Olurinde A. Oni, Kamal Gupta, Guoqing Chen, Mukut Sharma, Buddhadeb Dawn, Ram Sharma, Deepak Parashara, Virginia J. Savin, John A. Ambrose, Rajat S. Barua 

Professional guidelines recommend testosterone replacement therapy (TRT) in patients with signs and symptoms of hypogonadism and documented evidence of low testosterone (T) levels.1 The diagnosis of late-onset hypogonadism is on the rise with estimates that nearly 2.4 million men aged 40–69 suffer from hypogonadism in the USA.2 Even though late-onset hypogonadism is not a universally accepted concept, and FDA has advised against T supplementation in men on the basis of age alone. However, in the last decade there has been a nearly 400% increase in the number of TRT prescriptions creating a billion dollar market.3 With such widespread and ever increasing use of TRT, there has been growing concern regarding its effect on mortality and cardiovascular (CV) outcomes. Read More